Clinical Trial Update: Evaluating the Safety and Protective Efficacy of a Single Dose of a Trivalent Live Attenuated Dengue Vaccine to Protect Against Infection With DENV-2 [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update evaluating safety and protective efficacy against dengue virus serotype 2 after a single dose of a trivalent live attenuated dengu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dengue

Drugs mentioned

• Trivalent live attenuated dengue vaccine

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Dengue | Phase 1 | Status: COMPLETED